N@N

Jeffrey Silber Upgraded (BIIB) to Buy on, Oct 25th, 2017

Jeffrey Silber of BMO Capital, Upgraded "Biogen Inc." (BIIB) to Buy on, Oct 25th, 2017.

Jeffrey has made no other calls on BIIB in the last 4 months.

There are 10 other peers that have a rating on BIIB. Out of the 10 peers that are also analyzing BIIB, 3 agree with Jeffrey's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Robyn Karnauskas of "Citigroup" Downgraded from Strong Buy to Hold on, Monday, October 23rd, 2017
• Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $319 on, Friday, September 15th, 2017
• Eun Yang of "Jefferies" Initiated at Hold and Held Target at $310 on, Tuesday, July 11th, 2017

These are the ratings of the 7 analyists that currently disagree with Jeffrey

---

• Adnan Butt of "Guggenheim" Initiated at Strong Buy and Held Target at $402 on, Tuesday, October 24th, 2017
• Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $390 on, Monday, October 23rd, 2017
• Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $365 on, Wednesday, October 18th, 2017
• Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Thomas Shrader of "Stifel" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Thursday, October 5th, 2017
• Terence Flynn of "Goldman Sachs" Upgraded at Strong Buy on, Wednesday, August 16th, 2017

Contributing Sources

---